Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma

Overview of attention for article published in Science Advances, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

news: 5 news outlets
twitter: 14 X users

patent: 1 patent

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 8 news stories from 5 outlets.

Xenetic Biosciences : Updated 2021 Corporate Presentation (Form 8-K)

MarketScreener, 13 Sep 2021

Expanding the Potential of CAR T CellTherapy NASDAQ:XBIO xeneticbio.com InvestorPresentation September 2021 Forward-LookingStatem…

Xenetic Biosciences, Inc. Provides Business Outlook

Digital Journal, 08 Oct 2019

Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value…

News story from Finanz Nachrichten on Tuesday 08 October 2019

Finanz Nachrichten, 08 Oct 2019

Xenetic Biosciences, Inc. Provides Business Outlook

Bioportfolio, 08 Oct 2019

Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 4 additional news stories.